(1-benzylpiperidin-4-yl)(2,6-dichloropyrimidin-4-yl)-amine | 1072270-55-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-benzylpiperidin-4-yl)(2,6-dichloropyrimidin-4-yl)-amine
• 英文别名: N-(1-benzylpiperidin-4-yl)-2,6-dichloropyrimidin-4-amine
• CAS: 1072270-55-3
• 化学式: C₁₆H₁₈Cl₂N₄
• 分子量: 337.252
• InChiKey: OXJIDYTUBGJEPV-UHFFFAOYSA-N

物化性质

• 沸点：
  488.4±45.0 °C(predicted)
• 密度：
  1.343±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1-benzylpiperidin-4-yl)(2,6-dichloropyrimidin-4-yl)-amine 在 三乙胺 作用下， 以 甲醇 、 戊醇 为溶剂， 反应 46.0h， 生成 3-[3-(4-{[4-(1-benzylpiperidin-4-ylamino)-6-morpholin-4-yl-pyrimidin-2-ylamino]methyl}[1,2,3]triazol-1-yl)propoxy]propionic acid methyl ester
  参考文献：
  名称：

  Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c01912
• 作为产物：
  描述：

  2,4,6-三氯嘧啶 、 4-氨基-1-苄基哌啶 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 生成 (1-benzylpiperidin-4-yl)(2,6-dichloropyrimidin-4-yl)-amine
  参考文献：
  名称：

  Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond

  摘要：

  The function of the CXCR4/CXCL12 axis accounts for many disease indications, including tissue/nerve regeneration, cancer metastasis, and inflammation. Blocking CXCR4 signaling with its antagonists may lead to moving out CXCR4(+) cell types from bone marrow to peripheral circulation. We have discovered a novel series of pyrimidine-based CXCR4 antagonists, a representative (i.e., 16) of which was tolerated at a higher dose and showed better HSC-mobilizing ability at the maximal response dose relative to the approved drug 1 (AMD3100), and thus considered a potential drug candidate for PBSCT indication. Docking compound 16 into the X-ray crystal structure of CXCR4 receptor revealed that it adopted a spider-like conformation striding over both major and minor subpockets. This putative binding mode provides a new insight into CXCR4 receptor-ligand interactions for further structural modifications.

  DOI：

  10.1021/acs.jmedchem.7b01322

文献信息

• PHARMACEUTICAL COMPOUNDS
  申请人：Baker Stewart James

  公开号：US20100256143A1

  公开（公告）日：2010-10-07

  The invention provides a pyrimidine compound of formula (I): wherein R 1 and R 2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  本发明提供一种嘧啶化合物，其化学式为(I)：其中R1和R2具有本文中定义的任何值；或其药学上可接受的盐。该化合物是PI3K的抑制剂，因此可用于治疗由PI3激酶引起的异常细胞生长、功能或行为所导致的疾病和障碍，例如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌功能障碍和神经系统障碍。
• WO2008/125833
  申请人：——

  公开号：——

  公开（公告）日：——
• Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond
  作者：Chien-Huang Wu、Jen-Shin Song、Hsuan-Hao Kuan、Szu-Huei Wu、Ming-Chen Chou、Jiing-Jyh Jan、Lun K. Tsou、Yi-Yu Ke、Chiung-Tong Chen、Kai-Chia Yeh、Sing-Yi Wang、Teng-Kuang Yeh、Chen-Tso Tseng、Chen-Lung Huang、Mine-Hsine Wu、Po-Chu Kuo、Chia-Jui Lee、Kak-Shan Shia

  DOI：10.1021/acs.jmedchem.7b01322

  日期：2018.2.8

  The function of the CXCR4/CXCL12 axis accounts for many disease indications, including tissue/nerve regeneration, cancer metastasis, and inflammation. Blocking CXCR4 signaling with its antagonists may lead to moving out CXCR4(+) cell types from bone marrow to peripheral circulation. We have discovered a novel series of pyrimidine-based CXCR4 antagonists, a representative (i.e., 16) of which was tolerated at a higher dose and showed better HSC-mobilizing ability at the maximal response dose relative to the approved drug 1 (AMD3100), and thus considered a potential drug candidate for PBSCT indication. Docking compound 16 into the X-ray crystal structure of CXCR4 receptor revealed that it adopted a spider-like conformation striding over both major and minor subpockets. This putative binding mode provides a new insight into CXCR4 receptor-ligand interactions for further structural modifications.
• [EN] PYRIMIDINE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINE ET LEUR UTILISATION
  申请人：[en]YEH, Teng-Kuang

  公开号：WO2023014611A1

  公开（公告）日：2023-02-09

  Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy- induced peripheral neuropathy.
• Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy
  作者：Yi-Fan Chen、Chien-Huang Wu、Li-Hsien Chen、Hao-Wei Lee、Jinq-Chyi Lee、Teng-Kuang Yeh、Jang-Yang Chang、Ming-Chen Chou、Hui-Ling Wu、Yen-Po Lai、Jen-Shin Song、Kai-Chia Yeh、Chiung-Tong Chen、Chia-Jui Lee、Kak-Shan Shia、Meng-Ru Shen

  DOI：10.1021/acs.jmedchem.1c01912

  日期：2022.3.24